Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 561Leukemia 282Precursor Cell Lymphoblastic Leukemia-Lymphoma 235Myelodysplastic Syndromes 110Congenital Abnormalities 86Leukemia, Monocytic, Acute 84Leukemia, Myelomonocytic, Acute 82Leukemia, Erythroblastic, Acute 75Leukemia, Megakaryoblastic, Acute 72Lymphoma 65Burkitt Lymphoma 62Recurrence 61Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Lymphoma, Non-Hodgkin 41Blast Crisis 37Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 33Lymphoma, Large B-Cell, Diffuse 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 28Myeloproliferative Disorders 27Lymphoma, Follicular 27Lymphoma, Large-Cell, Immunoblastic 25Lymphoma, Mantle-Cell 24Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Hodgkin Disease 23Lymphoma, B-Cell, Marginal Zone 22Leukemia, Basophilic, Acute 22

Interventions

Cytarabine 2venetoclax 1pembrolizumab 1obinutuzumab 1neratinib 1idelalisib 1ibrutinib 1gilteritinib 1Surveys and Questionnaires 1Positron Emission Tomography Computed Tomography 1Mitoxantrone 1Interleukin-15 1Gemtuzumab 1Daunorubicin 1CPX-351 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease × Cytarabine × Other hematologic neoplasm × Clear all
NCT00788892 2018-01-12

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Jazz Pharmaceuticals

Phase 2 Completed
126 enrolled 12 charts
Other hematologic neoplasm

Disease, Leukemia, Leukemia, Myeloid, Acute

NCT00143975 2010-08-12

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

University of Ulm

Phase 2 Completed
95 enrolled
Other hematologic neoplasm

Disease, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡